01.04.2014 18:39:00
|
Eli Lilly and Company -- Moody's: Alimta patent ruling credit positive for Eli Lilly
New York, April 01, 2014 -- Moody's Investors Service commented that a US District Court ruling on Eli Lilly's Alimta patent is credit positive. The ruling significantly increases the likelihood that generic competition for the blockbuster chemotherapy drug will be pushed out to 2022 in the US, instead of 2016 when a separate patent expires.